naltrexone (BioDeep_00000398442)

Main id: BioDeep_00000001496

 


代谢物信息卡片


naltrexone

化学式: C20H23NO4 (341.16269980000004)
中文名称: 纳曲酮
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: C1CC1CN1CC[C@]23c4c5ccc(c4O[C@H]2C(=O)CC[C@]3([C@H]1C5)O)O
InChI: InChI=1S/C20H23NO4/c22-13-4-3-12-9-15-20(24)6-5-14(23)18-19(20,16(12)17(13)25-18)7-8-21(15)10-11-1-2-11/h3-4,11,15,18,22,24H,1-2,5-10H2

描述信息

N - Nervous system > N07 - Other nervous system drugs > N07B - Drugs used in addictive disorders > N07BB - Drugs used in alcohol dependence
D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids
COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials
D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents
D002491 - Central Nervous System Agents > D009292 - Narcotic Antagonists
D002491 - Central Nervous System Agents > D000427 - Alcohol Deterrents
C78272 - Agent Affecting Nervous System > C681 - Opiate Antagonist
Corona-virus
Coronavirus
SARS-CoV-2
COVID-19
SARS-CoV
COVID19
SARS2
SARS

同义名列表

1 个代谢物同义名

naltrexone



数据库引用编号

23 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:

  • PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。



文献列表

  • Yi Hu, Periyannan Velu, Pejman Rohani, Mohammad Hassan Sohouli. Changes in lipid profile and glucose metabolism following administration of bupropion alone or in combination with naltrexone: A systematic review and meta-regression analysis. European journal of clinical investigation. 2023 Nov; ?(?):e14122. doi: 10.1111/eci.14122. [PMID: 37929909]
  • Konstantinos Stefanakis, Alexander Kokkinos, Georgia Argyrakopoulou, Sofia K Konstantinidou, Stamatia Simati, Matina Kouvari, Ajay Kumar, Bhanu Kalra, Melina Kumar, Nikolaos Bontozoglou, Konstantina Kyriakopoulou, Christos S Mantzoros. Circulating levels of proglucagon-derived peptides are differentially regulated by the glucagon-like peptide-1 agonist liraglutide and the centrally acting naltrexone/bupropion and can predict future weight loss and metabolic improvements: A 6-month long interventional study. Diabetes, obesity & metabolism. 2023 09; 25(9):2561-2574. doi: 10.1111/dom.15141. [PMID: 37246799]
  • Asser F Bedair, Ahmed Wahid, Nesrine S El-Mezayen, Amira F El-Yazbi, Hadeel A Khalil, Nayera W Hassan, Elham A Afify. Nicorandil/ morphine crosstalk accounts for antinociception and hepatoprotection in hepatic fibrosis in rats: Distinct roles of opioid/cGMP and NO/KATP pathways. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2023 Jun; 165(?):115068. doi: 10.1016/j.biopha.2023.115068. [PMID: 37392650]
  • Judith I Tsui, Aimee N C Campbell, Martina Pavlicova, Tse-Hwei Choo, Joshua D Lee, Ryan R Cook, Matisyahu Shulman, Edward V Nunes, John Rotrosen. Methamphetamine/amphetamine use over time among persons with opioid use disorders treated with buprenorphine/naloxone versus extended-release naltrexone. Drug and alcohol dependence. 2022 Jul; 236(?):109469. doi: 10.1016/j.drugalcdep.2022.109469. [PMID: 35605529]
  • Anupam Ankit, Basudeb Das, Pranjal Dey, Khitish Kumar Kshitiz, Christoday Raja Jayant Khess. Efficacy of continuous theta burst stimulation - repetitive trancranial magnetic stimulation on the orbito frontal cortex as an adjunct to naltrexone in patients of opioid use disorder and its correlation with serum BDNF levels: a sham-controlled study. Journal of addictive diseases. 2022 Jul; 40(3):373-381. doi: 10.1080/10550887.2021.2007716. [PMID: 34823444]
  • Bertram Pitt, Ashley M Tate, David Gluck, Robert S Rosenson, Sascha N Goonewardena. Repurposing low-dose naltrexone for the prevention and treatment of immunothrombosis in COVID-19. European heart journal. Cardiovascular pharmacotherapy. 2022 06; 8(4):402-405. doi: 10.1093/ehjcvp/pvac014. [PMID: 35179184]
  • Hesham Salem, Ebtihal Samir, Dina Z Mazen, Hoda Madian, Alshimaa E Elkhateeb, Manar Elaraby, Manar I Rasekh, Aliaa Gamal. Spectrofluorimetric first derivative synchronous approach for determination of olanzapine and samidorphan used for treatment of schizophrenia in pharmaceutical formulations and human plasma. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy. 2022 Jun; 274(?):121105. doi: 10.1016/j.saa.2022.121105. [PMID: 35272122]
  • Elizabeth Klein, Maria Karim, Randie Kim, Kristen Lo Sicco, Jerry Shapiro. Reversible Hair Loss in Lichen Planopilaris: Regrowth With Low-Dose Naltrexone and Platelet-Rich Plasma. Journal of drugs in dermatology : JDD. 2022 Jun; 21(6):671-673. doi: 10.36849/jdd.6810. [PMID: 35674753]
  • Thuy Nguyen, Engy Ziedan, Kosali Simon, Jennifer Miles, Stephen Crystal, Hillary Samples, Sumedha Gupta. Racial and Ethnic Disparities in Buprenorphine and Extended-Release Naltrexone Filled Prescriptions During the COVID-19 Pandemic. JAMA network open. 2022 06; 5(6):e2214765. doi: 10.1001/jamanetworkopen.2022.14765. [PMID: 35648400]
  • Sina Zimmermann, Bettina C Thomas, Johannes Krisam, Ronald Limprecht, Christina Klose, Manuel Stenger, Madeleine Pourbaix, Marcel Ries, Sabine Vollstaedt-Klein, Anne Koopmann, Bernd Lenz, Falk Kiefer, Patrick Bach. ON-ICE trial: Investigation of the combined effects of oxytocin and naltrexone on stress-induced and alcohol cue-induced craving in alcohol use disorder-Study protocol of a phase II randomised double-blind placebo-controlled parallel-group trial. BMJ open. 2022 04; 12(4):e059672. doi: 10.1136/bmjopen-2021-059672. [PMID: 35410938]
  • Seon Yeong Kim, Dong Won Shin, SungIll Suh, Jae Chul Cheong, Jin Young Kim. Monitoring alcohol-use-disorder medication compliance by LC-MS/MS determination of urinary ethyl glucuronide, acamprosate, naltrexone, and 6β-naltrexol using zirconia-based hybrid solid-phase extraction. Journal of pharmaceutical and biomedical analysis. 2022 Apr; 212(?):114615. doi: 10.1016/j.jpba.2022.114615. [PMID: 35219960]
  • Paul J Joudrey, Marynia Kolak, Qinyun Lin, Susan Paykin, Vidal Anguiano, Emily A Wang. Assessment of Community-Level Vulnerability and Access to Medications for Opioid Use Disorder. JAMA network open. 2022 04; 5(4):e227028. doi: 10.1001/jamanetworkopen.2022.7028. [PMID: 35438757]
  • Nessreen Ghanem, Devin Dromgoole, Ahmad Hussein, Richard T Jermyn. Review of medication-assisted treatment for opioid use disorder. Journal of osteopathic medicine. 2022 Mar; 122(7):367-374. doi: 10.1515/jom-2021-0163. [PMID: 35285220]
  • Laura J Cremer, Amy Board, Gery P Guy, Lyna Schieber, Alice Asher, Erin M Parker. Trends in pharmacy-based dispensing of buprenorphine, extended-release naltrexone, and naloxone during the COVID-19 pandemic by age and sex - United States, March 2019 - December 2020. Drug and alcohol dependence. 2022 03; 232(?):109192. doi: 10.1016/j.drugalcdep.2021.109192. [PMID: 35065513]
  • Frederico G S Toledo, William F Martin, Linda Morrow, Carine Beysen, Daiva Bajorunas, Ying Jiang, Bernard L Silverman, David McDonnell, Mark N Namchuk, John W Newcomer, Christine Graham. Insulin and glucose metabolism with olanzapine and a combination of olanzapine and samidorphan: exploratory phase 1 results in healthy volunteers. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2022 02; 47(3):696-703. doi: 10.1038/s41386-021-01244-7. [PMID: 34887529]
  • Mark G Papich, Roger J Narayan. Naloxone and nalmefene absorption delivered by hollow microneedles compared to intramuscular injection. Drug delivery and translational research. 2022 02; 12(2):376-383. doi: 10.1007/s13346-021-01096-0. [PMID: 34817831]
  • Joseph P Schacht, Michaela Hoffman, Brian H Chen, Raymond F Anton. Epigenetic moderators of naltrexone efficacy in reducing heavy drinking in Alcohol Use Disorder: a randomized trial. The pharmacogenomics journal. 2022 02; 22(1):1-8. doi: 10.1038/s41397-021-00250-8. [PMID: 34381173]
  • Abhinav Choubey, Budheswar Dehury, Sunil Kumar, Bikash Medhi, Prosenjit Mondal. Naltrexone a potential therapeutic candidate for COVID-19. Journal of biomolecular structure & dynamics. 2022 02; 40(3):963-970. doi: 10.1080/07391102.2020.1820379. [PMID: 32930058]
  • Hossein Kamali, Malihe Karimi, Mohammadreza Abbaspour, Azadeh Nadim, Farzin Hadizadeh, Elham Khodaverdi, Farhad Eisvand. Comparison of lipid liquid crystal formulation and Vivitrol® for sustained release of Naltrexone: In vitro evaluation and pharmacokinetics in rats. International journal of pharmaceutics. 2022 Jan; 611(?):121275. doi: 10.1016/j.ijpharm.2021.121275. [PMID: 34748809]
  • Siri Shastry, Ishak Nobel, Lisa R Allen, Lynne D Richardson, Kavey Vidal, Alex F Manini. Prior use of medications for opioid use disorder in ED patients with opioid overdose: prevalence, misuse and overdose severity. The American journal of emergency medicine. 2022 Jan; 51(?):114-118. doi: 10.1016/j.ajem.2021.10.012. [PMID: 34735968]
  • Ping Yang, Leyao Xiao, Fei Zhao, Wei He, Guijuan Zhang, Yongjing Tang, Yinghua Chen, Qijiao Cheng, Yihuai He. Effects of Naltrexone on Expression of Lipid Metabolism-Related Proteins in Liver Steatosis Induced by Endoplasmic Reticulum Stress in Mice. Contrast media & molecular imaging. 2022; 2022(?):6572499. doi: 10.1155/2022/6572499. [PMID: 35685666]
  • Kim Juhani Blomqvist, Katarzyna Anna Dudek, Hanna Viisanen, Kert Mätlik, Fredrik Harry Gustav Ahlström, Jouko Laitila, Eija Anneli Kalso, Pekka Veli Rauhala, Tuomas Olavi Lilius. Antagonism of peripheral opioid receptors by methylnaltrexone does not prevent morphine tolerance in rats. Journal of neuroscience research. 2022 01; 100(1):329-338. doi: 10.1002/jnr.24638. [PMID: 32459013]
  • Cecilie Siggaard Knoph, Mathias Ellgaard Cook, Camilla Ann Fjelsted, Srdan Novovic, Michael Bau Mortensen, Liv Bjerre Juul Nielsen, Mark Berner Hansen, Jens Brøndum Frøkjær, Søren Schou Olesen, Asbjørn Mohr Drewes. Effects of the peripherally acting μ-opioid receptor antagonist methylnaltrexone on acute pancreatitis severity: study protocol for a multicentre double-blind randomised placebo-controlled interventional trial, the PAMORA-AP trial. Trials. 2021 Dec; 22(1):940. doi: 10.1186/s13063-021-05885-3. [PMID: 34924020]
  • Ryan R Cook, Randy Torralva, Caroline King, Paula J Lum, Hansel Tookes, Canyon Foot, Pamela Vergara-Rodriguez, Allan Rodriguez, Laura Fanucchi, Gregory M Lucas, Elizabeth N Waddell, P Todd Korthuis. Associations between fentanyl use and initiation, persistence, and retention on medications for opioid use disorder among people living with uncontrolled HIV disease. Drug and alcohol dependence. 2021 11; 228(?):109077. doi: 10.1016/j.drugalcdep.2021.109077. [PMID: 34600253]
  • Indira Purushothaman, Ian S Zagon, Joseph W Sassani, Patricia J McLaughlin. Ocular surface complications in diabetes: The interrelationship between insulin and enkephalin. Biochemical pharmacology. 2021 10; 192(?):114712. doi: 10.1016/j.bcp.2021.114712. [PMID: 34324868]
  • Sidnee L Hedrick, Dan Luo, Sophia Kaska, Kumar Kulldeep Niloy, Karen Jackson, Rupam Sarma, Jamie Horn, Caroline Baynard, Markos Leggas, Eduardo R Butelman, Mary Jeanne Kreek, Thomas E Prisinzano. Design, synthesis, and preliminary evaluation of a potential synthetic opioid rescue agent. Journal of biomedical science. 2021 Sep; 28(1):62. doi: 10.1186/s12929-021-00758-y. [PMID: 34503531]
  • Lei Sun, Zoe Barter, Lisa von Moltke, Karen Rowland Yeo. Using physiologically-based pharmacokinetic modeling for predicting the effects of hepatic impairment on the pharmacokinetics of olanzapine and samidorphan given as a combination tablet. CPT: pharmacometrics & systems pharmacology. 2021 09; 10(9):1071-1080. doi: 10.1002/psp4.12675. [PMID: 34185436]
  • Elizabeth Needham Waddell, Sandra A Springer, Lisa A Marsch, David Farabee, Robert P Schwartz, Amesika Nyaku, Rusty Reeves, Keith Goldfeld, Ryan D McDonald, Mia Malone, Anna Cheng, Elizabeth C Saunders, Laura Monico, Jan Gryczynski, Kathleen Bell, Kasey Harding, Sandra Violette, Thomas Groblewski, Wendy Martin, Kasey Talon, Nicole Beckwith, Andrew Suchocki, Randy Torralva, Jennifer P Wisdom, Joshua D Lee. Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults (EXIT-CJS). Journal of substance abuse treatment. 2021 09; 128(?):108389. doi: 10.1016/j.jsat.2021.108389. [PMID: 33865691]
  • Todd M Hillhouse, Keith M Olson, James E Hallahan, Lauren G Rysztak, Bryan F Sears, Claire Meurice, Mehrnoosh Ostovar, Peyton O Koppenhaver, Joshua L West, Emily M Jutkiewicz, Stephen M Husbands, John R Traynor. The Buprenorphine Analogue BU10119 Attenuates Drug-Primed and Stress-Induced Cocaine Reinstatement in Mice. The Journal of pharmacology and experimental therapeutics. 2021 09; 378(3):287-299. doi: 10.1124/jpet.121.000524. [PMID: 34183434]
  • Indira Purushothaman, Ian S Zagon, Joseph W Sassani, Shouhao Zhou, Patricia J McLaughlin. Sex differences in the magnitude of diabetic ocular surface complications: Role of serum OGF. Physiology & behavior. 2021 08; 237(?):113436. doi: 10.1016/j.physbeh.2021.113436. [PMID: 33905807]
  • Lukas Dehe, Mohammed Shaqura, Michael Nordine, Helmut Habazettl, Petra von Kwiatkowski, Helena Schluchter, Mehdi Shakibaei, Shaaban A Mousa, Michael Schäfer, Sascha Treskatsch. Chronic Naltrexone Therapy Is Associated with Improved Cardiac Function in Volume Overloaded Rats. Cardiovascular drugs and therapy. 2021 08; 35(4):733-743. doi: 10.1007/s10557-020-07132-4. [PMID: 33484395]
  • Julie M Donohue, Marian P Jarlenski, Joo Yeon Kim, Lu Tang, Katherine Ahrens, Lindsay Allen, Anna Austin, Andrew J Barnes, Marguerite Burns, Chung-Chou H Chang, Sarah Clark, Evan Cole, Dushka Crane, Peter Cunningham, David Idala, Stefanie Junker, Paul Lanier, Rachel Mauk, Mary Joan McDuffie, Shamis Mohamoud, Nathan Pauly, Logan Sheets, Jeffery Talbert, Kara Zivin, Adam J Gordon, Susan Kennedy. Use of Medications for Treatment of Opioid Use Disorder Among US Medicaid Enrollees in 11 States, 2014-2018. JAMA. 2021 07; 326(2):154-164. doi: 10.1001/jama.2021.7374. [PMID: 34255008]
  • Steven D Shirk, Victoria Ameral, Shane W Kraus, Joseph Houchins, Megan Kelly, Kendra Pugh, Erin Reilly, Nitigna Desai. Buprenorphine Naloxone and Extended Release Injectable Naltrexone for the Treatment of Opioid Use Disorder Among a Veteran Patient Sample: A Retrospective Chart Review. Journal of dual diagnosis. 2021 Jul; 17(3):207-215. doi: 10.1080/15504263.2021.1942380. [PMID: 34176448]
  • P A Marathe, S D Satam, S B Raut, Y C Shetty, S G Pooja, A A Raut, P P Kale, N N Rege. Effect of Withania somnifera (L.) Dunal aqueous root extract on reinstatement using conditioned place preference and brain GABA and dopamine levels in alcohol dependent animals. Journal of ethnopharmacology. 2021 Jun; 274(?):113304. doi: 10.1016/j.jep.2020.113304. [PMID: 32920131]
  • Ruichao Mao, Lihua Bie, Maofeng Xu, Xiaocong Wang, Jun Gao. Antiviral drug design based on the opening mechanism of spike glycoprotein in SARS-CoV-2. Physical chemistry chemical physics : PCCP. 2021 Jun; 23(22):12549-12558. doi: 10.1039/d1cp01045j. [PMID: 34008647]
  • René S Kahn, Bernard L Silverman, Lauren DiPetrillo, Christine Graham, Ying Jiang, Jiani Yin, Adam Simmons, Vasudev Bhupathi, Bei Yu, Sergey Yagoda, Craig Hopkinson, David McDonnell. A phase 3, multicenter study to assess the 1-year safety and tolerability of a combination of olanzapine and samidorphan in patients with schizophrenia: Results from the ENLIGHTEN-2 long-term extension. Schizophrenia research. 2021 06; 232(?):45-53. doi: 10.1016/j.schres.2021.04.009. [PMID: 34015555]
  • Ani Gasparyan, Francisco Navarrete, Jorge Manzanares. The administration of sertraline plus naltrexone reduces ethanol consumption and motivation in a long-lasting animal model of post-traumatic stress disorder. Neuropharmacology. 2021 05; 189(?):108552. doi: 10.1016/j.neuropharm.2021.108552. [PMID: 33819457]
  • Marissa J Metz, Caitlin M Daimon, Shane T Hentges. Reported Benefits of Low-Dose Naltrexone Appear to Be Independent of the Endogenous Opioid System Involving Proopiomelanocortin Neurons and β-Endorphin. eNeuro. 2021 May; 8(3):. doi: 10.1523/eneuro.0087-21.2021. [PMID: 34031099]
  • Eri Hikita, Mituko Hashimoto, Takeo Yasu, Mikio Shirota, Kazuha Nakamura. Efficacy of Naldemedine in the Management of Constipation in a Patient with Severe COVID-19 Receiving Mechanical Ventilation. Journal of palliative medicine. 2021 05; 24(5):651-652. doi: 10.1089/jpm.2021.0028. [PMID: 33544649]
  • Christopher J Donelan, Edmond Hayes, Ruth A Potee, Levin Schwartz, Elizabeth A Evans. COVID-19 and treating incarcerated populations for opioid use disorder. Journal of substance abuse treatment. 2021 05; 124(?):108216. doi: 10.1016/j.jsat.2020.108216. [PMID: 33288348]
  • Lei Sun, Lisa von Moltke, Karen Rowland Yeo. Application of Physiologically Based Pharmacokinetic Modeling to Predict the Effect of Renal Impairment on the Pharmacokinetics of Olanzapine and Samidorphan Given in Combination. Clinical pharmacokinetics. 2021 05; 60(5):637-647. doi: 10.1007/s40262-020-00969-w. [PMID: 33313995]
  • Nelson Jeng-Yeou Chear, Francisco León, Abhisheak Sharma, Siva Rama Raju Kanumuri, Grant Zwolinski, Khalil A Abboud, Darshan Singh, Luis F Restrepo, Avi Patel, Takato Hiranita, Surash Ramanathan, Aidan J Hampson, Lance R McMahon, Christopher R McCurdy. Exploring the Chemistry of Alkaloids from Malaysian Mitragyna speciosa (Kratom) and the Role of Oxindoles on Human Opioid Receptors. Journal of natural products. 2021 04; 84(4):1034-1043. doi: 10.1021/acs.jnatprod.0c01055. [PMID: 33635670]
  • Chethan Bachireddy, Mishka Terplan. Payer strategies to ensure access to care for individuals with opioid use disorder during COVID-19. The American journal of managed care. 2021 03; 27(3):91-92. doi: 10.37765/ajmc.2021.88522. [PMID: 33720664]
  • Butch KuKanich, Kate KuKanich, Charles W Locuson, David C Rankin, Alyson H Fitzgerald, Peter Cho, Marissa S Komp. Multiple-dose pharmacokinetics and opioid effects of a novel analgesic with a deterrent to human opioid abuse (methadone-fluconazole-naltrexone) after oral administration in dogs. American journal of veterinary research. 2021 Mar; 82(3):171-180. doi: 10.2460/ajvr.82.3.171. [PMID: 33629900]
  • Minji Sohn, Jeffery C Talbert, Zhengyan Huang, Carrie Oser, Patricia R Freeman. Trends in Urine Drug Monitoring Among Persons Receiving Long-Term Opioids and Persons with Opioid Use Disorder in the United States. Pain physician. 2021 03; 24(2):E249-E256. doi: 10.36076/ppj.2021.24.e249-e256. [PMID: 33740362]
  • Ian S Zagon, Joseph W Sassani, Indira Purushothaman, Patricia J McLaughlin. Blockade of OGFr delays the onset and reduces the severity of diabetic ocular surface complications. Experimental biology and medicine (Maywood, N.J.). 2021 03; 246(5):629-636. doi: 10.1177/1535370220972060. [PMID: 33203224]
  • Mary M Mitchell, Robert P Schwartz, Tse-Hwei Choo, Martina Pavlicova, Kevin E O'Grady, Jan Gryczynski, Maxine L Stitzer, Edward V Nunes, John Rotrosen. An alternative analysis of illicit opioid use during treatment in a randomized trial of extended-release naltrexone versus buprenorphine-naloxone: A per-protocol and completers analysis. Drug and alcohol dependence. 2021 02; 219(?):108422. doi: 10.1016/j.drugalcdep.2020.108422. [PMID: 33352487]
  • Christopher M Jones, Gery P Guy, Amy Board. Comparing actual and forecasted numbers of unique patients dispensed select medications for opioid use disorder, opioid overdose reversal, and mental health, during the COVID-19 pandemic, United States, January 2019 to May 2020. Drug and alcohol dependence. 2021 02; 219(?):108486. doi: 10.1016/j.drugalcdep.2020.108486. [PMID: 33421802]
  • Fengbao Luo, Renfang Xu, Guanglai Song, Dong Xue, Xiaozhou He, Ying Xia. Alleviation of TGF-β1 induced tubular epithelial-mesenchymal transition via the δ-opioid receptor. The FEBS journal. 2021 02; 288(4):1243-1258. doi: 10.1111/febs.15459. [PMID: 32563195]
  • Madhukar H Trivedi, Robrina Walker, Walter Ling, Adriane Dela Cruz, Gaurav Sharma, Thomas Carmody, Udi E Ghitza, Aimee Wahle, Mora Kim, Kathy Shores-Wilson, Steven Sparenborg, Phillip Coffin, Joy Schmitz, Katharina Wiest, Gavin Bart, Susan C Sonne, Sidarth Wakhlu, A John Rush, Edward V Nunes, Steven Shoptaw. Bupropion and Naltrexone in Methamphetamine Use Disorder. The New England journal of medicine. 2021 01; 384(2):140-153. doi: 10.1056/nejmoa2020214. [PMID: 33497547]
  • Kevin Wenzel, Marc Fishman. Mobile van delivery of extended-release buprenorphine and extended-release naltrexone for youth with OUD: An adaptation to the COVID-19 emergency. Journal of substance abuse treatment. 2021 01; 120(?):108149. doi: 10.1016/j.jsat.2020.108149. [PMID: 33303086]
  • Chirag Patel, Mark D Meadowcroft, Ian S Zagon, Patricia J McLaughlin. [Met5]-enkephalin preserves diffusion metrics in EAE mice. Brain research bulletin. 2020 12; 165(?):246-252. doi: 10.1016/j.brainresbull.2020.10.015. [PMID: 33141073]
  • Marc Fishman, Kevin Wenzel, Jennifer Scodes, Martina Pavlicova, Joshua D Lee, John Rotrosen, Edward Nunes. Young Adults Have Worse Outcomes Than Older Adults: Secondary Analysis of a Medication Trial for Opioid Use Disorder. The Journal of adolescent health : official publication of the Society for Adolescent Medicine. 2020 12; 67(6):778-785. doi: 10.1016/j.jadohealth.2020.07.038. [PMID: 32873500]
  • Rachel E Gicquelais, Amy S B Bohnert, Laura Thomas, Betsy Foxman. Opioid agonist and antagonist use and the gut microbiota: associations among people in addiction treatment. Scientific reports. 2020 11; 10(1):19471. doi: 10.1038/s41598-020-76570-9. [PMID: 33173098]
  • Brian Chan, Michele Freeman, Chelsea Ayers, P Todd Korthuis, Robin Paynter, Karli Kondo, Devan Kansagara. A systematic review and meta-analysis of medications for stimulant use disorders in patients with co-occurring opioid use disorders. Drug and alcohol dependence. 2020 11; 216(?):108193. doi: 10.1016/j.drugalcdep.2020.108193. [PMID: 32861136]
  • David R Maguire, Lisa R Gerak, Jesus J Sanchez, Martin A Javors, Alex Disney, Stephen M Husbands, Charles P France. Effects of acute and repeated treatment with methocinnamox, a mu opioid receptor antagonist, on fentanyl self-administration in rhesus monkeys. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2020 11; 45(12):1986-1993. doi: 10.1038/s41386-020-0698-8. [PMID: 32375158]
  • Lisa L Wolfe, Travis Mays, Mark C Fisher, Michael W Miller. Tissue Residue Levels of the Tranquilizer Combination of Butorphanol, Azaperone, and Medetomidine, and the Antagonists, Naltrexone, Atipamezole, and Tolazoline, in Black Bears (Ursus americanus) Postimmobilization. Journal of wildlife diseases. 2020 10; 56(4):933-936. doi: 10.7589/jwd-d-19-00012. [PMID: 32348204]
  • Raymond F Anton, Konstantin E Voronin, Sarah W Book, Patricia K Latham, Patrick K Randall, Willam Bailey Glen, Michaela Hoffman, Joseph P Schacht. Opioid and Dopamine Genes Interact to Predict Naltrexone Response in a Randomized Alcohol Use Disorder Clinical Trial. Alcoholism, clinical and experimental research. 2020 10; 44(10):2084-2096. doi: 10.1111/acer.14431. [PMID: 32772383]
  • Toshiyuki Kanemasa, Takanobu Matsuzaki, Katsumi Koike, Minoru Hasegawa, Tsutomu Suzuki. Preventive effects of naldemedine, peripherally acting μ-opioid receptor antagonist, on morphine-induced nausea and vomiting in ferrets. Life sciences. 2020 Sep; 257(?):118048. doi: 10.1016/j.lfs.2020.118048. [PMID: 32622946]
  • Ning Liu, Mingxing Ma, Na Qu, Ruizhe Wang, Hao Chen, Fangzhu Hu, Song Gao, Fengping Shan. Low-dose naltrexone inhibits the epithelial-mesenchymal transition of cervical cancer cells in vitro and effects indirectly on tumor-associated macrophages in vivo. International immunopharmacology. 2020 Sep; 86(?):106718. doi: 10.1016/j.intimp.2020.106718. [PMID: 32585612]
  • Butch KuKanich, Kate KuKanich, David C Rankin, Charles W Locuson, Hyun Joo. Pharmacokinetics and pharmacodynamics of a novel analgesic with a deterrent to human opioid abuse (methadone-fluconazole-naltrexone) after oral administration in dogs. American journal of veterinary research. 2020 Aug; 81(8):656-664. doi: 10.2460/ajvr.81.8.656. [PMID: 32700999]
  • Jenny Boyer. COVID-19, Medication-Assisted Treatment, and Increased Risk for Further Respiratory Depression. The American journal of psychiatry. 2020 07; 177(7):636. doi: 10.1176/appi.ajp.2020.20030348. [PMID: 32605451]
  • Lei Sun, Sergey Yagoda, Hongqi Xue, Randy Brown, Narinder Nangia, David McDonnell, Bhaskar Rege, Lisa von Moltke, Borje Darpo. Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: Results from a phase 1 QT/QTc study. Progress in neuro-psychopharmacology & biological psychiatry. 2020 06; 100(?):109881. doi: 10.1016/j.pnpbp.2020.109881. [PMID: 32004636]
  • Kazuya Fukumura, Nao Kawaguchi, Toru Ishibashi, Ryuji Kubota, Yukio Tada, Eriko Ogura. Clinical Drug-Drug Interaction Studies to Evaluate the Effects of a P-Glycoprotein Inhibitor, CYP3A Inhibitors, and a CYP3A Inducer on the Pharmacokinetics of Naldemedine in Healthy Subjects. Clinical drug investigation. 2020 Jun; 40(6):529-540. doi: 10.1007/s40261-020-00902-w. [PMID: 32323104]
  • E Andrew Townsend, Paul T Bremer, Kaycee E Faunce, S Stevens Negus, Alaina M Jaster, Hannah L Robinson, Kim D Janda, Matthew L Banks. Evaluation of a Dual Fentanyl/Heroin Vaccine on the Antinociceptive and Reinforcing Effects of a Fentanyl/Heroin Mixture in Male and Female Rats. ACS chemical neuroscience. 2020 05; 11(9):1300-1310. doi: 10.1021/acschemneuro.0c00064. [PMID: 32271538]
  • Robertas Badaras, Tomas Jovaisa, Indre Lapinskiene, Juozas Ivaskevicius. Dose Escalation of Naltrexone to Reduce Stress Responses Associated With Opioid Antagonist Induction: A Double-blind Randomized Trial. Journal of addiction medicine. 2020 May; 14(3):253-260. doi: 10.1097/adm.0000000000000560. [PMID: 31609865]
  • Meng-Yun Li, Chao Chen, Zheng-Gang Wang, Jian-Juan Ke, Xiao-Bo Feng. Effect of Nalmefene on Delayed Neurocognitive Recovery in Elderly Patients Undergoing Video-assisted Thoracic Surgery with One Lung Ventilation. Current medical science. 2020 Apr; 40(2):380-388. doi: 10.1007/s11596-020-2170-8. [PMID: 32337700]
  • Cornel N Stanciu, Samantha Gnanasegaram. Naltrexone and Its Noroxymorphone Minor Metabolite - A Case Report. Journal of psychoactive drugs. 2020 Apr; 52(2):169-171. doi: 10.1080/02791072.2019.1649507. [PMID: 31366308]
  • Jeffery D Foss, Sunil U Nayak, Christopher S Tallarida, Daniel J Farkas, Sara J Ward, Scott M Rawls. Mitragynine, bioactive alkaloid of kratom, reduces chemotherapy-induced neuropathic pain in rats through α-adrenoceptor mechanism. Drug and alcohol dependence. 2020 04; 209(?):107946. doi: 10.1016/j.drugalcdep.2020.107946. [PMID: 32145665]
  • Edward V Nunes, Adam Bisaga, Evgeny Krupitsky, Narinder Nangia, Bernard L Silverman, Sarah C Akerman, Maria A Sullivan. Opioid use and dropout from extended-release naltrexone in a controlled trial: implications for mechanism. Addiction (Abingdon, England). 2020 02; 115(2):239-246. doi: 10.1111/add.14735. [PMID: 31313402]
  • Neili Xu, Yuejiao Wang, Shuai Zhao, Ting Jiao, Hongxia Xue, Fengping Shan, Ning Zhang. Naltrexone (NTX) relieves inflammation in the collagen-induced- arthritis (CIA) rat models through regulating TLR4/NFκB signaling pathway. International immunopharmacology. 2020 Feb; 79(?):106056. doi: 10.1016/j.intimp.2019.106056. [PMID: 31865244]
  • Zhu Luo, Jia Miao, Shiqing Shu, Ying Wang, Xiaohong Zhu, Chao Hu, Yali Shen. Pharmacokinetics and Bioequivalence Evaluation of a New Oxycodone Tamper-Resistant Tablet Administered with an Opioid Antagonist in Patients with Chronic Pain. Clinical drug investigation. 2020 Feb; 40(2):139-148. doi: 10.1007/s40261-019-00870-w. [PMID: 31679120]
  • David Wiercigroch, Hasan Sheikh, Jennifer Hulme. A rapid access to addiction medicine clinic facilitates treatment of substance use disorder and reduces substance use. Substance abuse treatment, prevention, and policy. 2020 01; 15(1):4. doi: 10.1186/s13011-019-0250-1. [PMID: 31931831]
  • Alshimaa Aboalsoud, Sabah H El-Ghaiesh, Fleur F Abd Elmonem, Mohammed L Salem, Mohamed N Abdel Rahman. The effect of low-dose naltrexone on solid Ehrlich carcinoma in mice: The role of OGFr, BCL2, and immune response. International immunopharmacology. 2020 Jan; 78(?):106068. doi: 10.1016/j.intimp.2019.106068. [PMID: 31835085]
  • Melanie Kienzl, Martin Storr, Rudolf Schicho. Cannabinoids and Opioids in the Treatment of Inflammatory Bowel Diseases. Clinical and translational gastroenterology. 2020 01; 11(1):e00120. doi: 10.14309/ctg.0000000000000120. [PMID: 31899693]
  • Lei Sun, Sergey Yagoda, Baiyun Yao, Christine Graham, Lisa von Moltke. Combination of Olanzapine and Samidorphan Has No Clinically Significant Effect on the Pharmacokinetics of Lithium or Valproate. Clinical drug investigation. 2020 Jan; 40(1):55-64. doi: 10.1007/s40261-019-00860-y. [PMID: 31584140]
  • Meredith Spada, Julie Kmiec, Jody B Glance, Priya Gopalan. Consideration of opioid agonist treatment in a pregnant adolescent: A case report and literature review. Substance abuse. 2020; 41(2):181-185. doi: 10.1080/08897077.2019.1635970. [PMID: 31361590]
  • Brian Chan, Michele Freeman, Karli Kondo, Chelsea Ayers, Jessica Montgomery, Robin Paynter, Devan Kansagara. Pharmacotherapy for methamphetamine/amphetamine use disorder-a systematic review and meta-analysis. Addiction (Abingdon, England). 2019 12; 114(12):2122-2136. doi: 10.1111/add.14755. [PMID: 31328345]
  • Gretchen Hermes, Scott M Hyman, Nia Fogelman, Thomas R Kosten, Rajita Sinha. Lofexidine in Combination With Oral Naltrexone for Opioid Use Disorder Relapse Prevention: A Pilot Randomized, Double-Blind, Placebo-Controlled Study. The American journal on addictions. 2019 11; 28(6):480-488. doi: 10.1111/ajad.12942. [PMID: 31448846]
  • Philip Krieter, Shwe Gyaw, Roger Crystal, Phil Skolnick. Fighting Fire with Fire: Development of Intranasal Nalmefene to Treat Synthetic Opioid Overdose. The Journal of pharmacology and experimental therapeutics. 2019 11; 371(2):409-415. doi: 10.1124/jpet.118.256115. [PMID: 30940694]
  • Rebekah D Tenney, Steven Blake, Paul T Bremer, Bin Zhou, Candy S Hwang, Justin L Poklis, Kim D Janda, Matthew L Banks. Vaccine blunts fentanyl potency in male rhesus monkeys. Neuropharmacology. 2019 11; 158(?):107730. doi: 10.1016/j.neuropharm.2019.107730. [PMID: 31369740]
  • Shane Darke, Michael Farrell, Johan Duflou, Briony Larance, Julia Lappin. Circumstances of death of opioid users being treated with naltrexone. Addiction (Abingdon, England). 2019 11; 114(11):2000-2007. doi: 10.1111/add.14729. [PMID: 31278812]
  • Tyler S Oesterle, Nuria J Thusius, Teresa A Rummans, Mark S Gold. Medication-Assisted Treatment for Opioid-Use Disorder. Mayo Clinic proceedings. 2019 10; 94(10):2072-2086. doi: 10.1016/j.mayocp.2019.03.029. [PMID: 31543255]
  • Mona Moradi, Amir Hossein Doustimotlagh, Ahmad Reza Dehpour, Nastaran Rahimi, Abolfazl Golestani. The influence of TRAIL, adiponectin and sclerostin alterations on bone loss in BDL-induced cirrhotic rats and the effect of opioid system blockade. Life sciences. 2019 Sep; 233(?):116706. doi: 10.1016/j.lfs.2019.116706. [PMID: 31369758]
  • Iuliia Makarenko, Iryna Pykalo, Sandra A Springer, Alyona Mazhnaya, Ruthanne Marcus, Sergii Filippovich, Sergii Dvoriak, Frederick L Altice. Treating opioid dependence with extended-release naltrexone (XR-NTX) in Ukraine: Feasibility and three-month outcomes. Journal of substance abuse treatment. 2019 09; 104(?):34-41. doi: 10.1016/j.jsat.2019.05.008. [PMID: 31370983]
  • Scott E Hemby, Scot McIntosh, Francisco Leon, Stephen J Cutler, Christopher R McCurdy. Abuse liability and therapeutic potential of the Mitragyna speciosa (kratom) alkaloids mitragynine and 7-hydroxymitragynine. Addiction biology. 2019 09; 24(5):874-885. doi: 10.1111/adb.12639. [PMID: 29949228]
  • Shuichi Ohnishi, Kazuya Fukumura, Ryuji Kubota, Toshihiro Wajima. Absorption, distribution, metabolism, and excretion of radiolabeled naldemedine in healthy subjects. Xenobiotica; the fate of foreign compounds in biological systems. 2019 Sep; 49(9):1044-1053. doi: 10.1080/00498254.2018.1536815. [PMID: 30351180]
  • Elisha M Wachman, Kelley Saia, Melissa Miller, Eduardo Valle, Hira Shrestha, Ginny Carter, Martha Werler, Hendree Jones. Naltrexone Treatment for Pregnant Women With Opioid Use Disorder Compared With Matched Buprenorphine Control Subjects. Clinical therapeutics. 2019 09; 41(9):1681-1689. doi: 10.1016/j.clinthera.2019.07.003. [PMID: 31358302]
  • Vipul Kumar, Hong Lu, Marjie Hard, Lisa von Moltke. Characterization of the Pharmacokinetics of Samidorphan in Healthy Volunteers: Absolute Bioavailability and the Effect of Food and Age. Drugs in R&D. 2019 Sep; 19(3):277-287. doi: 10.1007/s40268-019-00280-5. [PMID: 31463821]
  • Eric R Kinzler, Carmela Pantaleon, Matthew Iverson, Stefan Aigner. A Randomized, Crossover Study on the Effect of Food on the Pharmacokinetic Characteristics of Morphine ARER (MorphaBond™ ER), an Abuse-Deterrent Formulation of Extended-Release Morphine. Advances in therapy. 2019 09; 36(9):2394-2401. doi: 10.1007/s12325-019-01022-4. [PMID: 31278694]
  • Joseph S Gimbel, Richard L Rauck, Almasa Bass, Jacquelyn Wilson, Glenn Pixton, Bimal Malhotra, Gary Wilson, Gernot Wolfram. Effects of naltrexone exposure observed in two phase three studies with ALO-02, an extended-release oxycodone surrounding sequestered naltrexone. Journal of opioid management. 2019 Sep; 15(5):417-427. doi: 10.5055/jom.2019.0530. [PMID: 31849032]
  • Francesco Franchi, Fabiana Rollini, Yongwhi Park, Jenny Hu, Megha Kureti, Jose Rivas Rios, Gabriel Faz, Dmitry Yaranov, Latonya Been, Andres M Pineda, Siva Suryadevara, Daniel Soffer, Martin M Zenni, Theodore A Bass, Dominick J Angiolillo. Effects of Methylnaltrexone on Ticagrelor-Induced Antiplatelet Effects in Coronary Artery Disease Patients Treated With Morphine. JACC. Cardiovascular interventions. 2019 08; 12(16):1538-1549. doi: 10.1016/j.jcin.2019.05.028. [PMID: 31377269]
  • Philip Krieter, Shwe Gyaw, C Nora Chiang, Roger Crystal, Phil Skolnick. Enhanced Intranasal Absorption of Naltrexone by Dodecyl Maltopyranoside: Implications for the Treatment of Opioid Overdose. Journal of clinical pharmacology. 2019 07; 59(7):947-957. doi: 10.1002/jcph.1384. [PMID: 30698833]
  • Philip Krieter, C Nora Chiang, Shwe Gyaw, Phil Skolnick, Rebekah Snyder. Pharmacokinetic Interaction between Naloxone and Naltrexone Following Intranasal Administration to Healthy Subjects. Drug metabolism and disposition: the biological fate of chemicals. 2019 07; 47(7):690-698. doi: 10.1124/dmd.118.085977. [PMID: 30992306]
  • Sarah F Cordery, Stephen M Husbands, Christopher P Bailey, Richard H Guy, M Begoña Delgado-Charro. Simultaneous Transdermal Delivery of Buprenorphine Hydrochloride and Naltrexone Hydrochloride by Iontophoresis. Molecular pharmaceutics. 2019 06; 16(6):2808-2816. doi: 10.1021/acs.molpharmaceut.9b00337. [PMID: 31070927]
  • Lei Sun, David McDonnell, Miao Yu, Vipul Kumar, Lisa von Moltke. A Phase I Open-Label Study to Evaluate the Effects of Rifampin on the Pharmacokinetics of Olanzapine and Samidorphan Administered in Combination in Healthy Human Subjects. Clinical drug investigation. 2019 May; 39(5):477-484. doi: 10.1007/s40261-019-00775-8. [PMID: 30888624]
  • Takaaki Komatsu, Soh Katsuyama, Fumihide Takano, Takemasa Okamura, Chikai Sakurada, Minoru Tsuzuki, Kakuyou Ogawa, Atsuhito Kubota, Osamu Morinaga, Kenji Tabata, Tsukasa Sakurada. Possible involvement of the μ opioid receptor in the antinociception induced by sinomenine on formalin-induced nociceptive behavior in mice. Neuroscience letters. 2019 04; 699(?):103-108. doi: 10.1016/j.neulet.2019.01.035. [PMID: 30690119]
  • Evgeny Krupitsky, Elena Blokhina, Edwin Zvartau, Elena Verbitskaya, Dmitri Lioznov, Tatiana Yaroslavtseva, Vladimir Palatkin, Marina Vetrova, Natalia Bushara, Andrei Burakov, Dmitri Masalov, Olga Mamontova, Daniel Langleben, Sabrina Poole, Robert Gross, George Woody. Slow-release naltrexone implant versus oral naltrexone for improving treatment outcomes in people with HIV who are addicted to opioids: a double-blind, placebo-controlled, randomised trial. The lancet. HIV. 2019 04; 6(4):e221-e229. doi: 10.1016/s2352-3018(18)30362-x. [PMID: 30880163]
  • Brantley P Jarvis, August F Holtyn, Anthony DeFulio, Mikhail N Koffarnus, Jeannie-Marie S Leoutsakos, Annie Umbricht, Michael Fingerhood, George E Bigelow, Kenneth Silverman. The effects of extended-release injectable naltrexone and incentives for opiate abstinence in heroin-dependent adults in a model therapeutic workplace: A randomized trial. Drug and alcohol dependence. 2019 04; 197(?):220-227. doi: 10.1016/j.drugalcdep.2018.12.026. [PMID: 30852374]